News

Qilu Pharma got CEP for Ondansetron HCl

ABOUT US

News

Qilu Pharma got CEP for Ondansetron HCl

Release time：

2009-12-28

Recently, we received CEP for Ondansetron HCl from EDQM. It is the second CEP granted to Qilu Pharma this year while the other is for Terbinafine HCl.

EDQM issued the certificate based on the review of our DMF without site inspection. It demonstrate that Qilu has a very strong capability on regulatory affairs and quality management.

Qilu Pharma Won “National Science & Technology Progress Award”

Qilu's Projects of Pemetrexed Disodium and Risperidone are appraised by Shandong Science & Technology

Related News

Qilu Pharmaceutical ranks No.3 in the list of "Top 100 Enterprises in Chinese Pharmaceutical industry”

2024-09-30

Qilu Launches First Generic Version of Invega Sustenna® (Paliperidone Palmitate Suspension for Injection) in China

2023-10-12

Qilu Pharmaceutical launched the first innovative drug in China

2023-09-01

Qilu Pharmaceutical Group Awarded as Socially Responsible Enterprises (Entrepreneurs) in 2022

2023-04-04

Qilu Pharmaceutical ranks No.5 in the list of "Top 100 Enterprises in Chinese Pharmaceutical Industry”